Sientra Inc. (SIEN) Stock Price Up 14.5%
Sientra Inc. (NASDAQ:SIEN) rose 14.5% on Tuesday . The company traded as high as $8.41 and last traded at $8.14, with a volume of 888,624 shares. The stock had previously closed at $7.11.
Separately, Zacks Investment Research lowered Sientra from a “hold” rating to a “sell” rating in a research note on Wednesday, April 13th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $28.50.
The stock’s market cap is $147.47 million. The company’s 50 day moving average price is $6.96 and its 200 day moving average price is $7.19.
Sientra (NASDAQ:SIEN) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by $0.05. The business earned $6.20 million during the quarter, compared to the consensus estimate of $4.80 million. Equities research analysts expect that Sientra Inc. will post ($2.03) EPS for the current year.
An institutional investor recently bought a new position in Sientra stock. Globeflex Capital L P bought a new stake in Sientra Inc. (NASDAQ:SIEN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 181,200 shares of the company’s stock, valued at approximately $1,073,000. Globeflex Capital L P owned about 1.01% of Sientra at the end of the most recent reporting period.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.